Octagam (Human Normal Immunoglobulin)

Human normal immunoglobulin, the active ingredient in Octagam, is an immunoglobulin presented as a solution for injection for intravenous use. It treats primary immunodeficiency and other immune‑mediated disorders in patients requiring immunoglobulin replacement.

GNH USA supplies Octagam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Octagam, an immunoglobulin replacement therapy, is used to manage disorders involving immune deficiency or dysregulation.

- Primary immunodeficiency: restores IgG levels to reduce frequency and severity of infections. - Immune thrombocytopenic purpura (ITP): raises platelet counts by modulating auto‑antibody activity. - Chronic inflammatory demyelinating polyneuropathy (CIDP): improves muscle strength and functional ability through immune modulation. - Kawasaki disease: reduces coronary artery inflammation and supports recovery in acute phases.

Adverse reactions to Octagam may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often occurring during or after infusion. - Fever: transient elevation of body temperature. - Chills or rigors: shivering sensations during infusion. - Fatigue: generalized tiredness post‑administration. - Nausea: mild gastrointestinal discomfort. - Infusion‑related reactions: erythema, itching, or mild hypotension.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical intervention. - Thromboembolic events: blood clots such as deep‑vein thrombosis or stroke. - Acute renal failure: sudden loss of kidney function, especially with high‑dose infusions. - Aseptic meningitis: inflammation of the meninges without infection. - Hemolysis: destruction of red blood cells leading to anemia. - Severe thrombocytopenia: marked drop in platelet count.

Before initiating Octagam therapy, several precautions should be considered to ensure safety and efficacy. - Patient assessment: evaluate immunoglobulin levels and infection history before treatment. - Infusion rate: start at a slow rate and adjust based on tolerance to minimize reactions. - Renal function: monitor kidney function, especially in patients with pre‑existing renal impairment. - Thrombotic risk: assess for risk factors such as hypercoagulability or cardiovascular disease. - Concomitant medications: review use of anticoagulants or nephrotoxic drugs for potential interactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the solution.

Octagam can interact with certain medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Live vaccines: concurrent administration may reduce vaccine effectiveness. - Anticoagulants (e.g., warfarin): increased risk of bleeding due to altered coagulation.

Moderate Interactions (Monitor Closely): - Other immunoglobulin products: may compound immunoglobulin load and affect tolerance. - Monoclonal antibodies (e.g., rituximab): potential for altered pharmacokinetics. - Nephrotoxic agents (e.g., aminoglycosides): heightened risk of renal impairment. - Diuretics: may exacerbate fluid shifts during infusion. - ACE inhibitors: monitor blood pressure and renal function.